港股異動 | 中國有贊(8083.HK)升超7%盤中破頂 CEO料今年交易額將破千億
格隆匯11月30日丨中國有贊(8083.HK)午後急升至11%,盤中高見2.23港元創歷史新高,現漲7.5%,暫成交6.1億港元,總市值370.8億港元。在有贊八週年生態大會上,有贊CEO白鴉透露,在2020年前三季度,有贊服務商家的交易額已達723億元,2020年全年交易額將破千億,甚至還會往上再拔高不少。年交易額千億,國內達到這一規模的電子商務企業屈指可數。在私域運營領域,這一數據更加具備歷史意義。另外,中國有贊獲納入MSCI中國全流通指數,於今日收盤後生效。國盛證券曾指,預計中國有贊2020-2022年收入約18.5/26.2/37.4億元,維持“買入”評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.